[
  {
    "ts": "2025-12-05T02:48:10+00:00",
    "headline": "Pfizer Inc. (PFE): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Pfizer Inc. on HatedMoats’s Substack. In this article, we will summarize the bulls’ thesis on PFE. Pfizer Inc.’s share was trading at $25.27 as of December 1st. PFE’s trailing and forward P/E were 14.97 and 8.50 respectively according to Yahoo Finance. Pfizer Inc. (PFE) has emerged from the post-COVID period as a transformed […]",
    "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-bull-case-024810028.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "5ae0dd83-34c4-3fe2-87a5-8c3f940ac1e1",
      "content": {
        "id": "5ae0dd83-34c4-3fe2-87a5-8c3f940ac1e1",
        "contentType": "STORY",
        "title": "Pfizer Inc. (PFE): A Bull Case Theory",
        "description": "",
        "summary": "We came across a bullish thesis on Pfizer Inc. on HatedMoats’s Substack. In this article, we will summarize the bulls’ thesis on PFE. Pfizer Inc.’s share was trading at $25.27 as of December 1st. PFE’s trailing and forward P/E were 14.97 and 8.50 respectively according to Yahoo Finance. Pfizer Inc. (PFE) has emerged from the post-COVID period as a transformed […]",
        "pubDate": "2025-12-05T02:48:10Z",
        "displayTime": "2025-12-05T02:48:10Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/3052554a5673500b2147b2f3c83a2fd5",
          "originalWidth": 768,
          "originalHeight": 509,
          "caption": "Analyst Says Pfizer (PFE) Stock Will ‘Move Too Fast to Catch’",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pg1ruI8jmytZrC3KfUN.Ng--~B/aD01MDk7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/3052554a5673500b2147b2f3c83a2fd5.cf.webp",
              "width": 768,
              "height": 509,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LMsGcyNZ22D5ZdRWNHAfRw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/3052554a5673500b2147b2f3c83a2fd5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-bull-case-024810028.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-bull-case-024810028.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-05T10:42:00+00:00",
    "headline": "Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Sanofi",
    "summary": "Eli Lilly, Johnson & Johnson and Sanofi stay in focus as Big Pharma shows signs of recovery amid innovation, M&A and easing industry pressures.",
    "url": "https://finance.yahoo.com/news/zacks-industry-outlook-highlights-eli-104200778.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "bd8b6121-4225-363e-b9ee-371573819c87",
      "content": {
        "id": "bd8b6121-4225-363e-b9ee-371573819c87",
        "contentType": "STORY",
        "title": "Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Sanofi",
        "description": "",
        "summary": "Eli Lilly, Johnson & Johnson and Sanofi stay in focus as Big Pharma shows signs of recovery amid innovation, M&A and easing industry pressures.",
        "pubDate": "2025-12-05T10:42:00Z",
        "displayTime": "2025-12-05T10:42:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/74bab520128f201c7e6cc3f67385e761",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tugIemz.T.iquqxVIoxpHw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/74bab520128f201c7e6cc3f67385e761.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SHyaOdZAc4DXCya2O4.DtQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/74bab520128f201c7e6cc3f67385e761.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/zacks-industry-outlook-highlights-eli-104200778.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/zacks-industry-outlook-highlights-eli-104200778.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "SNY"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-05T04:02:16+00:00",
    "headline": "3 Reasons PFE is Risky and 1 Stock to Buy Instead",
    "summary": "Pfizer has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 11% to $25.67 per share while the index has gained 15.3%.",
    "url": "https://finance.yahoo.com/news/3-reasons-pfe-risky-1-040216664.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "c4327b44-7f9c-3499-a2cd-c7e6d7777069",
      "content": {
        "id": "c4327b44-7f9c-3499-a2cd-c7e6d7777069",
        "contentType": "STORY",
        "title": "3 Reasons PFE is Risky and 1 Stock to Buy Instead",
        "description": "",
        "summary": "Pfizer has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 11% to $25.67 per share while the index has gained 15.3%.",
        "pubDate": "2025-12-05T04:02:16Z",
        "displayTime": "2025-12-05T04:02:16Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/1ff5bd386bd84b91b34108fd5f310eca",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "PFE Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o3tZoPUio75qXATbHoc_Hg--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/1ff5bd386bd84b91b34108fd5f310eca.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o5rZqD7vIoFGnsFYAS_Ztw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/1ff5bd386bd84b91b34108fd5f310eca.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/3-reasons-pfe-risky-1-040216664.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-reasons-pfe-risky-1-040216664.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-05T15:25:00+00:00",
    "headline": "2 Headwinds Facing Pfizer Stock Going Into 2026",
    "summary": "There is plenty to be wary of with this drugmaker, but there are also reasons to be optimistic.",
    "url": "https://www.fool.com/investing/2025/12/05/2-headwinds-facing-pfizer-stock-going-into-2026/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "68ea6f79-0369-3225-bfb5-52e7d5e70dd5",
      "content": {
        "id": "68ea6f79-0369-3225-bfb5-52e7d5e70dd5",
        "contentType": "STORY",
        "title": "2 Headwinds Facing Pfizer Stock Going Into 2026",
        "description": "",
        "summary": "There is plenty to be wary of with this drugmaker, but there are also reasons to be optimistic.",
        "pubDate": "2025-12-05T15:25:00Z",
        "displayTime": "2025-12-05T15:25:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/b82600f088e0a0aec9c8a81f81a038d1",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Person working at a desk.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QCDfl1DKQllYROqrL81eWw--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/b82600f088e0a0aec9c8a81f81a038d1.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G_NP5KyRm3lTEGmRYMoxLA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/b82600f088e0a0aec9c8a81f81a038d1.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/12/05/2-headwinds-facing-pfizer-stock-going-into-2026/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-headwinds-facing-pfizer-stock-152500086.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-05T15:24:08+00:00",
    "headline": "3 Low-Volatility Stocks with Warning Signs",
    "summary": "Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.",
    "url": "https://finance.yahoo.com/news/3-low-volatility-stocks-warning-152408446.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "b5633de5-c9a0-3d6b-8c3b-2479a9eb563d",
      "content": {
        "id": "b5633de5-c9a0-3d6b-8c3b-2479a9eb563d",
        "contentType": "STORY",
        "title": "3 Low-Volatility Stocks with Warning Signs",
        "description": "",
        "summary": "Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.",
        "pubDate": "2025-12-05T15:24:08Z",
        "displayTime": "2025-12-05T15:24:08Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/1ff5bd386bd84b91b34108fd5f310eca",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "PFE Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o3tZoPUio75qXATbHoc_Hg--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/1ff5bd386bd84b91b34108fd5f310eca.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o5rZqD7vIoFGnsFYAS_Ztw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/1ff5bd386bd84b91b34108fd5f310eca.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/3-low-volatility-stocks-warning-152408446.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-low-volatility-stocks-warning-152408446.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "AFL"
            },
            {
              "symbol": "EXPO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-05T14:23:00+00:00",
    "headline": "Can DefenCath Continue to Aid CorMedix's Long-Term Growth Ahead?",
    "summary": "CRMD's lead product, DefenCath, generates $167.6M in sales in the first nine months of 2025, with market exclusivity through 2033 likely to provide growth momentum.",
    "url": "https://finance.yahoo.com/news/defencath-continue-aid-cormedixs-long-142300172.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "019e99d6-377e-35f1-9f10-2a3c9cc6bea0",
      "content": {
        "id": "019e99d6-377e-35f1-9f10-2a3c9cc6bea0",
        "contentType": "STORY",
        "title": "Can DefenCath Continue to Aid CorMedix's Long-Term Growth Ahead?",
        "description": "",
        "summary": "CRMD's lead product, DefenCath, generates $167.6M in sales in the first nine months of 2025, with market exclusivity through 2033 likely to provide growth momentum.",
        "pubDate": "2025-12-05T14:23:00Z",
        "displayTime": "2025-12-05T14:23:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TNBAnrhWOnvvvNSvMEIuFg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rP7ZEHNft_Sb_FB9M.3i3w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/defencath-continue-aid-cormedixs-long-142300172.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/defencath-continue-aid-cormedixs-long-142300172.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRMD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]